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Abstract
Community-acquired pneumonia (CAP) is a common and potentially serious illness that is associated with
morbidity and mortality. Although medical care has improved during the past decades, it is still potentially lethal.
Streptococcus pneumoniae is the most frequent microorganism isolated. Treatment includes mandatory antibiotic
therapy and organ support as needed. There are several antibiotic therapy regimens that include b-lactams or
macrolides or fluoroquinolones alone or in combination. Combination antibiotic therapy achieves a better outcome
compared with monotherapy and it should be given in the following subset of patients with CAP: outpatients with
comorbidities and previous antibiotic therapy, nursing home patients with CAP, hospitalized patients with severe
CAP, bacteremic pneumococcal CAP, presence of shock, and necessity of mechanical ventilation. Better outcome is
associated with combination therapy that includes a macrolide for wide coverage of atypical pneumonia,
polymicrobial pneumonia, or resistant Streptococcus pneumoniae. Macrolides have shown different properties other
than antimicrobial activity, such as anti-inflammatory properties. Although this evidence comes from observational,
most of them retrospective and nonblinded studies, the findings are consistent. Ideally, a prospective, multicenter,
randomized trial should be performed to confirm these findings.
Introduction
Community-acquired pneumonia (CAP) is a common
and potentially serious illness that is associated with
morbidity and mortality [1]. Only half of the cases had
an etiology microorganism identified. Bacteria are the
most common identifiable cause; Streptococcus pneumo-
niae is the single most common bacterium responsible.
Antibiotic therapy is begun empirically, because the cau-
sative organism is not identified in a proportion of
patients [1-4]. Approximately 10% of patients hospita-
lized with CAP are bacteremic [5]. Bacteremic Strepto-
coccus pneumoniae pneumonia is the number one cause
of mortality, representing up to 70% of all CAP deaths.
Although medical care has improved during the past
decades, bacteremic pneumococcal pneumonia is still
lethal. Explanations for this situation could be the pre-
sence of immune-compromised patients, aging popula-
tion, or comorbid conditions. But there are more
explanations. A severity assessment score based on the
PIRO (Predisposition, Insult, Response, and Organ dys-
function) concept was assessed, including comorbidities,
age greater than 70 years, multilobar opacities in chest x-
ray, shock, severe hypoxemia, acute renal failure, bactere-
mia, and acute respiratory distress syndrome. The mean
PIRO score was significantly higher in nonsurvivors than
in survivors. Furthermore, analysis of variance showed
that higher levels of PIRO score were significantly asso-
ciated with higher mortality, prolonged length of stay in
the intensive care unit (ICU), and days of mechanical
ventilation. PIRO score for CAP can be used to predict
28-day mortality in CAP patients who require ICU
admission [6]. Bacterial load may identify potential candi-
dates for adjunctive therapy, ICU admission, and more
aggressive management. High bacterial load appears to
be significantly associated with worse outcomes [7].
Treatment of CAP continues to be a challenge in 21
st
century. Recommendations for CAP therapy are differ-
ent, depending on whether patients require hospitaliza-
tion (20%) or are treated as outpatients (80%) [8]. Other
issues for treatment recommendations include the emer-
gence of antibiotic resistance among Streptococcus pneu-
moniae and mono versus combination antibiotic
therapy. Combination therapy should be defined as the
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tam, macrolide, or fluoroquinolone. Monotherapy is the
use of only one of them.
Antimicrobial therapy remains a controversial issue to
treat CAP. Until better diagnostic tests are available in
the clinical setting, initial treatment is usually empiric.
To recommend mono versus combination therapy, we
should differentiate between outpatients with CAP and
patients who require hospitalization, hemodynamic sup-
port, or mechanical ventilation.
Ambulatory setting
In Canada and the United States, macrolides remain the
recommended first-line therapy for outpatients with
CAP but without comorbidities. Common risk factors
for CAP include age greater than 65 years, smoking,
alcohol consumption, chronic lung diseases, mechanical
obstruction of airways, aspiration of oropharyngeal or
gastric contents, pulmonary edema, uremia, and malnu-
trition [9].
The recommended empirical antibiotics for outpatient
therapy of CAP has been published recently in the
Infectious Diseases Society of America (IDSA)/American
Thoracic Society (ATS) consensus guidelines on the
management of community-acquired pneumonia in
adults [1]. For previously healthy patients without recent
antibiotic therapy within 3 months, a macrolide or doxy-
cycline are recommended. Macrolides remain effective
for patients with mild to moderate-severe CAP with no
risk factors [10]. For previously healthy patients but
with antibiotic therapy within 3 months, guidelines
recommend azithromycin or clarithromycin, plus a
high-dose amoxicillin (4 g/day) or amoxicillin-clavula-
nate (4 g/day), or a respiratory fluoroquinolone alone. If
there are comorbidities (chronic obstructive pulmonary
disease [COPD], diabetes, renal or congestive heart fail-
ure, malignancy) but without recent antibiotic therapy,
empirical therapy should start with azithromycin or clar-
ithromycin, or a respiratory fluoroquinolone alone. If
comorbidities and previous antibiotic therapy within 3
months, azithromycin or clarithromycin should be used,
plus high-dose amoxicillin, amoxicillin-clavulanate, cef-
podoxime, cefprozil, or cefuroxime, or a respiratory
fluoroquinolone.
A respiratory fluoroquinolone is one with predictable
activity against pneumococcus, such as levofloxacin or
moxifloxacin. They are recommended if there is a docu-
mented allergy to b-lactams, first-line therapy fails, or
against highly resistant pneumococcus prevalence. Anae-
robic coverage should be given if loss of consciousness
or gingival or esophageal disease. In the nursing home
without hospitalization, a respiratory fluoroquinolone or
amoxicillin-clavulanate plus a macrolide is recom-
mended as the first-choice [10].
Almost all of the clinical studies comparing newer
fluoroquinolones with the standard therapeutic regimen
have been designed to reveal noninferiority or bioequi-
valence. Therefore, high-risk patients were usually
excluded from these clinical trials. An outpatient trial
that compared two new fluoroquinolones–gemifloxacin
and trovafloxacin–showed high response rates of 92.5%
and 87.3%, respectively [11]. This trial, like others, was
not designed to evaluate fluoroquinolone efficacy in
severe pneumonia to gain approval from registration
agencies.
CAP that requires hospitalization
Two frequent recommended antibiotic regimens for
hospitalized patients with CAP are an extended-spec-
trum b-lactam (an extended-spectrum cephalosporin or
b-lactam-b-lactamase inhibitor) with a macrolide or an
antipneumococcal quinolone. These regimens have
activity against the major causes of CAP, including
drug-resistant Streptococcus pneumoniae [12-15]. Recent
evidence suggests the superiority of combination therapy
compared with monotherapy for subset populations,
particularly patients with severe CAP, bacteremic pneu-
mococcal CAP, or intubated CAP. Table 1 resumes all
of these studies [5,16-29]. Which combination of anti-
biotics are more effective remains unclear, although
many studies had focused on the combination of an
extended-spectrum cephalosporin plus a macrolide
[17,19-21,23]. Moreover, most of the studies regarding
this topic are retrospective or observational, giving
apparently weak scientific evidence.
Other studies, however, have refuted the advantages of
dual therapy versus monotherapy for CAP [30-33]
(Table 2). Burgess et al. [30] enrolled 213 patients trea-
ted with a nonpseudomonal third-generation cephalos-
porin with (116 patients) or without (97 patients) a
macrolide; the majority of them (66%) received erythro-
mycin. There were no statistical differences between
patients who did or did not receive a macrolide in terms
of comorbid illnesses, length of hospital stay (5.2 ± 2.8
vs. 5.2 ± 3.4 days, respectively), length of intravenous
a n t i b i o t i ct h e r a p y( 4 . 4±2 . 5v s .4 . 1±2 . 3d a y s ,r e s p e c -
tively), or mortality (0.9% vs. 3.1%, respectively; p =
0.333). This low mortality shows that those patients did
not have severe CAP. Data collected prospectively from
340 adult patients hospitalized in five countries with
bacteremic pneumococcal CAP and treated with b-lac-
tam ± macrolide were analyzed retrospectively to evalu-
ate the efficacy of this antimicrobial combination.
Univariate and multivariate analyses revealed no signifi-
cant effect on case fatality rate when a macrolide/b-lac-
tam regimen was used as initial therapy. Results were
not affected by severity of illness or by excluding
patients who died within 2 days of admission [31]. In a
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with severe sepsis or septic shock enrolled in two multi-
center clinical trials between 1994 and 1999, the subana-
lysis of 107 patients with pneumococcal sepsis, the case-
fatality rate was 20% (5/25) for patients who received
antibiotic monotherapy compared with 19.5% (16/82)
for patients who received combination therapy (adjusted
hazard ratio [HR], 1.1; 95% confidence interval [CI], 0.4-
3.1). Similarly, monotherapy did not increase the risk of
death (adjusted HR, 1.0; 95% CI, 0.2-4.8) among bac-
teremic patients (n = 75). However, the latter analysis
may have been underpowered (power, 58%) to detect a
difference in mortality [32].
Monotherapy with levofloxacin (500 mg every 12
hours) was compared with combination therapy
(ofloxacin 200 mg every 12 hours plus cefotaxime 1 g
every 8 hours) in a multinational trial of 398 patients
with CAP who required ICU admission, but who
required neither vasopressors nor mechanical ventila-
tion [33]. In this study, clinical success rates were the
same for both regimens (79% vs. 80%). These results
were not generalizable to intubated or patients with
shock. Although the numbers were small, more
patients treated with monotherapy failed a test of cure
(7/29 compared with 1/27 in the combination group)
[34].
Table 1 Published studies that favor combination therapy for in-hospital patients with CAP
Author Year Cohort Site Outcome Study design
Gleason et al. [16] 1999 Patients aged ≥ 65 years
with CAP
Ward Lower 30-day mortality with b-lactam plus macrolide Multicenter,
retrospective




Waterer et al. [19] 2001 Pneumococcal bacteremia Ward Lower hospital mortality with combination Multicenter,
retrospective
Brown et al. [21] 2003 CAP Ward Lower 30-day mortality with b-lactam plus macrolide Multicenter,
retrospective




Baddour et al. [22] 2004 Pneumococcal bacteremia Ward
ICU
Lower 14-day mortality with combination Multicenter,
prospective




2005 CAP Ward Lower mortality with b-lactam plus macrolide Multicenter,
prospective
Mortensen et al. [24] 2006 CAP Ward
ICU




Rodríguez et al. [25] 2007 CAP ICU Lower 28-day mortality with combination Multicenter,
retrospective
Metersky et al. [26] 2007 Pneumococcal bacteremia Ward Lower 30-day mortality with b-lactam plus macrolide Multicenter,
retrospective














Table 2 Trials without significant difference between antibiotic monotherapy and combination therapy for CAP
Author Year Cohort Outcome Study design
Burgess and
Lewiss [30]
2000 Hospitalized CAP without identified
microorganism








Harbarth et al. [32] 2005 Pneumococcal sepsis Lack of effect of combo therapy Multicenter,
retrospective
Leroy et al. [33] 2005 CAP without vasopressors Levofloxacin vs. cefotaxime + ofloxacin Multicenter,
retrospective
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with severe CAP for whom combination therapy is
clearly superior compared with monotherapy: severe
CAP, bacteremic pneumococcal CAP, CAP with shock,
and intubated CAP patients.
Severe CAP
Lodise et al. demonstrated that a combination therapy
of a b-lactam plus a macrolide had lower 14-day and
30-day mortality rates than with fluoroquinolone alone
(14-day rates: 8.2% vs. 26.8%, p = 0.02; 30-days rates:
18.4% vs. 36.6%, p =0 . 0 5 ) .H o w e v e r ,t h e s er e s u l t sw e r e
shown in patients with severe CAP, defined as a class V
Pneumonia Severity Index (PSI). No differences in mor-
tality between treatment groups were noted for the
lower PSI classes. The overall median length of stay
(LOS) was significantly longer for the combination ther-
apy group, but no difference in LOS was noted among
PSI class V patients [35]. Severe CAP also can be
defined as the presence of Streptococcus pneumoniae
bacteremia or the necessity for aggressive ICU manage-
ment due to shock, organ dysfunction, or need for
mechanical ventilation.
Bacteremic pneumococcal CAP
Recent observational studies suggest that combination
therapy for severe CAP confers a significant benefit for
patients, particularly those with bacteremic pneumococ-
cal disease [5,19-22]. This group of patients represents
only a small fraction of all of the CAP cases, but in
terms of mortality it is highly relevant.
Monotherapy may be suboptimal for patients with
severe bacteremic pneumococcal pneumonia. Waterer et
al. [19] found in patients with severe bacteremic pneu-
mococcal pneumonia a significantly higher mortality in
the single effective therapy group than within the dual
effective therapy group (p = 0.02; odds ratio [OR], 3.0;
95% CI, 1.2-7.6).
Martinez et al. [20] assessed the association between
inclusion of a macrolide in a b-lactam-based empirical
antibiotic regimen and mortality among patients with
bacteremic pneumococcal pneumonia. Multivariate ana-
lysis showed four variables to be independently asso-
ciated with death: shock (p < 0.0001), age ≥ 65 years (p
= 0.02), infections with pathogens that have resistance
to both penicillin and erythromycin (p =0 . 0 4 ) ,a n dn o
inclusion of a macrolide in the initial antibiotic regimen
(p = 0.03). For patients with bacteremic pneumococcal
pneumonia, not adding a macrolide to a b-lactam-based
initial antibiotic regimen is an independent predictor of
in-hospital mortality.
Weiss et al. [5] developed a similar retrospective study
on the outcome of bacteremic pneumococcal pneumo-
nia in adults. Data showed the same results. The
mortality rate was significantly higher in the group that
received monotherapy with a b-lactam compared with
that in the combination therapy group with a b-lactam
plus a macrolide (26% vs. 7.5%, respectively; p = 0.02).
Patients were comparable in terms of disease severity
using the severity index scores).
Although all of these studies were nonrandomized,
retrospective studies, they confirmed the importance of
initially adding a macrolide to a b-lactam regimen for
the treatment of bacteremic Streptococcus pneumoniae
pneumonia. However, these conclusions are limited to
patients with severe pneumonia for whom the mortality
risk is high. The value of these results cannot be extra-
polated for the treatment of inpatients with moderate
disease, for which fluoroquinolones still remain an
excellent therapy of choice [36].
CAP and shock
An observational study of patients with pneumonia who
require ICU care found that patients with CAP and
shock who were treated with combination antibiotic
therapy (58% with a third-generation cephalosporin plus
a macrolide), compared with those treated with mono-
therapy (42% fluoroquinolone), had a higher 28-day in-
ICU survival (HR, 2.69; 95% CI, 1.09-2.6). Survival was
not different between combination therapy and mono-
therapy for ICU patients without shock [25]. As other
studies, potential limitations are that it is an observa-
tional study and that the CAP severity stratification was
not standardized. Although dosing was given according
to 2007 IDSA/ATS guidelines [1] to define the appropri-
ateness of empirical treatment, underdosing is a com-
mon problem in patients with severe sepsis and
multiorgan dysfunction due to a higher volume of distri-
bution [37]. The consequence is finding lower-than-
expected plasma drug concentrations. However, if
decreased antibiotic clearance occurs, it can lead to drug
toxicity. Another limitation could be that by direct
extrapolation from the 2007 IDSA/ATS CAP guidelines
[1], Pseudomonas infection appears to have been sus-
pected a great deal; more patients were chosen to
receive quinolone therapy. It should not be surprising
that mortality would be higher in patients suspected of
possible Pseudomonas or multidrug resistant pathogens
infection [38].
Necessity of ventilator support
The effect on survival of using macrolides or fluoroqui-
nolones in combination therapy in a cohort of intubated
patients admitted to the ICU with severe CAP in 27
European ICUs was assessed [29]; 218 consecutive
patients who required invasive mechanical ventilation
for an admission diagnosis of CAP were recruited pro-
spectively. Monotherapy was given in 19.7% of patients
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therapy was in accordance with the 2007 IDSA/ATS
guidelines in 45.9% of patients [1]. Combination was
prescribed with macrolides in 46 patients and with
fluoroquinolones in 54 patients. In the macrolide group,
89.1% of patients received a third-generation cephalos-
porin, 4.3% a fourth-generation cephalosporin, and 6.5%
received piperacillin-tazobactam. Meanwhile, 40.7% of
the fluoroquinolone group received a third-generation
cephalosporin as combination therapy, 22.2% received a
carbapenem, and 25.9% received piperacillin-tazobactam.
Mortality in the ICU was significantly lower for subjects
who received a combination therapy with macrolides
compared with patients who received quinolones (26.1%
vs. 46.3%, p < 0.05). However, when excluding ciproflox-
acin, no significant differences were documented. Simi-
lar results were obtained with 30-day mortality. In this
cohort, a Cox regression analysis adjusted by severity
identified that macrolide use was associated with lower
ICU mortality (HR, 0.48; 95% CI, 0.23-0.97; p =0 . 0 4 )
compared with the use of fluoroquinolones. When more
severe patients with severe sepsis and septic shock were
analyzed, similar results were obtained (HR, 0.44; 95%
CI, 0.2-0.95; p = 0.03). Therefore, combination therapy
with macrolides should be preferred for invasive
mechanically ventilated patients with severe CAP.
Factors for combination therapy
Different factors may explain the superiority of combi-
nation therapy compared with monotherapy for the
treatment of patients with severe CAP. Combination
therapy has a better coverage of atypical microorganisms
in polymicrobial CAP, including both Chlamydia pneu-
monia and Mycoplasma pneumonia. It has been sug-
gested that a proportion of bacteremic Streptococcus
pneumoniae pneumonia patients have concomitant
Mycoplasma pneumoniae or, rarely, Legionella sp. infec-
tions [39].
Other factor for combination therapy superiority is the
fact that combination therapy acts at two different sites
in the bacteria: cell wall by b-lactams, and the inhibition
of protein synthesis by macrolides. Macrolides, more-
over, have been shown to have some very effective anti-
inflammatory properties [40]. Macrolides reduce the
release of interleukin-8 and tumor necrosis factor-a,
and the adherence of Streptococcus pneumoniae to
respiratory epithelial cells. Moreover, macrolides inhibit
protein synthesis, potentially decreasing the production
of virulence factors [41]. Other recent studies have sug-
gested that macrolides may have beneficial effects for
severe CAP [27] because of their immunomodulatory
effects rather than due to their antimicrobial properties
[42]. In Berlin at the 24
th European Society of Intensive
and Critical Care Medicine (ESICM) annual congress,
Dr. Restrepo presented a retrospected analysis of the
effect of macrolide therapy on 30- and 90-day mortality
for patients with severe sepsis that required mechanical
ventilation. After multivariable regression analysis,
macrolide use in patients with severe sepsis who
required intubation was associated with decreased 30-
day mortality (31% vs. 53%; OR, 0.49; 95% CI, 0.41-0.6)
and 90-day mortality (54% vs. 71%; OR, 0.59; 95% CI,
0.49-0.71) compared with nonmacrolide therapy after
adjusting for potential confounders [43]. Confirmatory,
randomized, control trials are needed to determine
whether macrolide therapy may be protective for septic
patients who require mechanical ventilation.
As PIRO approach defends, factors other than the
simple concept of in vitro activity alone are playing key
roles in bacteremic pneumonia. In fact, a lack of in vitro
synergy between erythromycin and cefotaxime combined
with penicillin against Streptococcus pneumoniae has
been published [44]. Therefore, the observed effect of
adding a macrolide in patients with severe CAP cannot
be attributed to a synergistic action between b-lactams
and macrolides [36].
Conclusions
Combination antibiotic therapy achieves a better out-
come compared with monotherapy, and it should be
given in the following subset of patients with CAP: out-
patients with comorbidities and previous antibiotic ther-
apy, nursing home patients with CAP, hospitalized
patients with severe CAP, bacteremic pneumococcal
CAP, presence of shock, and necessity of mechanical
ventilation (Table 3).
At ambulatory setting, if comorbidities and previous
antibiotic therapy within 3 months, azithromycin or
clarithromycin should be used, plus high-dose amoxicil-
lin, amoxicillin-clavulanate, cefpodoxime, cefprozil, or
cefuroxime, or a respiratory fluoroquinolone. In pre-
viously healthy patients without comorbidities or with-
out previous antibiotic therapy, monotherapy is still the
empirical initial recommended therapy. In the nursing
home without hospitalization, a respiratory fluoroquino-
lone or amoxicillin-clavulanate plus a macrolide is
recommended as the first choice.
Initial empirical combination therapy of a cephalos-
porin plus a macrolide for patients with CAP who
require hospitalization is associated with decreased mor-
tality and or shorter hospital stay than treatment with a
cephalosporin alone. For patients with moderate disease,
fluoroquinolones remain an excellent therapy of choice.
Although this evidence comes from observational, retro-
spective, and nonblinded studies, the findings are consis-
tent. For practical purposes, for the majority of patients
with CAP in ambulatory settings or hospitalized and not
severely ill, fluoroquinolone monotherapy remains an
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Otherwise, hospitalized patients with a severe CAP, bac-
teremia, ICU admission, or need for vasopressors or
mechanical ventilation may benefit from a dual antibio-
tic therapy that combines a third-generation cephalos-
porin and a macrolide. Ideally, a prospective,
randomized trial should be performed to confirm these
findings, although severe heterogenicity of patients is a
challenge to enroll patients and find differences as sev-
eral sepsis trials show.
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